Monneret C |
[Current impact of natural products in the discovery of anticancer drugs]. |
2010 |
Ann Pharm Fr |
pmid:20637355
|
Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Lopus M et al. |
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. |
2010 |
Mol. Cancer Ther. |
pmid:20937594
|
Oroudjev E et al. |
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. |
2010 |
Mol. Cancer Ther. |
pmid:20937595
|
Yao Y et al. |
Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. |
2010 |
J Sep Sci |
pmid:20235129
|
Wei GZ et al. |
A new antitumour ansamitocin from Actinosynnema pretiosum. |
2010 |
Nat. Prod. Res. |
pmid:20582809
|
Kovtun YV et al. |
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. |
2010 |
Cancer Res. |
pmid:20197459
|
Krop IE et al. |
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. |
2010 |
J. Clin. Oncol. |
pmid:20421541
|
Jumbe NL et al. |
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. |
2010 |
J Pharmacokinet Pharmacodyn |
pmid:20424896
|
Lin J et al. |
Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum. |
2011 |
Bioresour. Technol. |
pmid:20980145
|
Jia Y and Zhong JJ |
Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. |
2011 |
Bioresour. Technol. |
pmid:21907573
|
Junttila TT et al. |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. |
2011 |
Breast Cancer Res. Treat. |
pmid:20730488
|
Wu Y et al. |
N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. |
2011 |
Chembiochem |
pmid:21681880
|
Sun X et al. |
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. |
2011 |
Bioconjug. Chem. |
pmid:21391620
|
Kellogg BA et al. |
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. |
2011 |
Bioconjug. Chem. |
pmid:21425776
|
Lopus M |
Antibody-DM1 conjugates as cancer therapeutics. |
2011 |
Cancer Lett. |
pmid:21481526
|
Edwards A et al. |
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. |
2011 |
Dis Model Mech |
pmid:21504911
|
Barok M et al. |
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. |
2011 |
Breast Cancer Res. |
pmid:21510863
|
Zhao RY et al. |
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. |
2011 |
J. Med. Chem. |
pmid:21517041
|
Higa GM |
The microtubule as a breast cancer target. |
2011 |
Breast Cancer |
pmid:20862571
|
Allison M |
Can cancer clinical trials be fixed? |
2011 |
Nat. Biotechnol. |
pmid:21221090
|
Isakoff SJ and Baselga J |
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. |
2011 |
J. Clin. Oncol. |
pmid:21172881
|
Burris HA et al. |
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. |
2011 |
J. Clin. Oncol. |
pmid:21172893
|
Yang H et al. |
Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. |
2011 |
Cytoskeleton (Hoboken) |
pmid:21309084
|
Fishkin N et al. |
A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. |
2011 |
Chem. Commun. (Camb.) |
pmid:21874179
|
Hinow P et al. |
Modeling the effects of drug binding on the dynamic instability of microtubules. |
2011 |
Phys Biol |
pmid:21836336
|
LoRusso PM et al. |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
2011 |
Clin. Cancer Res. |
pmid:22003071
|
Blanc V et al. |
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. |
2011 |
Clin. Cancer Res. |
pmid:22003072
|
Mathew J and Perez EA |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. |
2011 |
Curr Opin Oncol |
pmid:21986845
|
Li Y et al. |
Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. |
2011 |
Chem. Biol. |
pmid:22195559
|
Knobloch T et al. |
Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. |
2011 |
Chembiochem |
pmid:22238146
|
Tuma RS |
Enthusiasm for antibody-drug conjugates. |
2011 |
J. Natl. Cancer Inst. |
pmid:21972230
|
Bertholjotti I |
[Antibody-drug conjugate--a new age for personalized cancer treatment]. |
2011 |
Chimia (Aarau) |
pmid:22026193
|
Beck A et al. |
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. |
2011 Jul-Aug |
MAbs |
pmid:21691144
|
Janthur WD et al. |
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. |
2012 |
Int J Mol Sci |
pmid:23443108
|
Gurtner K et al. |
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. |
2012 |
Radiother Oncol |
pmid:22100655
|
Eichner S et al. |
The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. |
2012 |
Angew. Chem. Int. Ed. Engl. |
pmid:22135226
|
Gupta M et al. |
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. |
2012 |
J Clin Pharmacol |
pmid:21953571
|
Shen BQ et al. |
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. |
2012 |
Nat. Biotechnol. |
pmid:22267010
|
Girish S et al. |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22271209
|
Garzone PD and Atkinson AJ |
In search of physiologically based distribution volume estimates for macromolecules. |
2012 |
Clin. Pharmacol. Ther. |
pmid:22992670
|
Matsubara Y |
A Meg by any other name. |
2012 |
Blood |
pmid:22956528
|
Taft F et al. |
Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. |
2012 |
Chemistry |
pmid:22170289
|
Kang Q et al. |
Biosynthesis of 3,5-AHBA-derived natural products. |
2012 |
Nat Prod Rep |
pmid:22193711
|
Davis JA et al. |
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. |
2012 |
Drug Metab. Dispos. |
pmid:22752008
|
Younes A et al. |
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. |
2012 |
J. Clin. Oncol. |
pmid:22753910
|
Erickson HK and Lambert JM |
ADME of antibody-maytansinoid conjugates. |
2012 |
AAPS J |
pmid:22875610
|
Damodaran S and Olson EM |
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. |
2012 |
Hosp Pract (1995) |
pmid:23299030
|
|
Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. |
2012 |
Harv Health Lett |
pmid:23243689
|
Barginear MF et al. |
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. |
2012 |
Mol. Med. |
pmid:23196784
|